Ligand Presents Multi-Dose Phase I Data on Lead SARM Molecule LGD-4033 at the Endocrine Society Annual Meeting

Ligand Pharmaceuticals Incorporated LGND today announced that data from a comprehensive Phase I multi-dose program with its selective androgen receptor modulator LGD-4033 was featured in a poster presentation today at the Endocrine Society Annual Meeting in Boston, June 4-7, 2011. In the Phase I clinical trial, the safety, tolerability and preliminary efficacy of LGD-4033 was evaluated in a double-blind, placebo-controlled, multiple ascending dose study. Healthy male subjects were randomized to receive 0.1, 0.3 or 1.0 mg LGD-4033 or placebo once daily over 21 days. The key findings include: LGD-4033 was safe and well tolerated at all doses following daily oral administration for three weeks in young healthy males. No clinically significant dose-related adverse events were reported. No clinically significant changes in liver function tests, PSA, hematocrit or ECG were seen. Positive dose-dependent trends in lean muscle mass increase were observed with drug-treated subjects. Positive dose-dependent trends in functional exercise and strength measures were consistent with anabolic activity